Merck & Co., Inc.
MRKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeMerck & Co., Inc. operates as a healthcare company worldwide. With a market capitalization of $296.11B, it sits in mega-cap territory. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$296.11B
Beta
0.20
P/E (TTM)
33.77
P/E (Fwd)
12.54
EPS (TTM)
$3.55
EPS (Fwd)
$9.56
ROE
18.9%
ROA
12.6%
Cash
$5.70B
Total Debt
$49.12B
Free CF
$14.05B
52W Change
56.0%
Annual Financials
Cash vs Debt
The company holds $5.70B in cash, though total debt stands at $49.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $14.05B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 18.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 12.6% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $59.28B (2022) to $65.01B (2025).
MRK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Merck & Co., Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Merck & Co., Inc.'s trajectory.